BioPharma Resources

Drug Trial Radar · NCT07589387

Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3

Transforming Hypertension Treatment in Nigeria Using a Type II Hybrid, Interrupted Time Series Design - Aim 3

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

2,800

Planned (sponsor's estimate)

Start

Feb 14, 2026

Primary completion

Apr 30, 2029

Study completion Jan 31, 2030

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); University of Abuja Teaching Hospital
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Health services research
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.

Conditions

  • Diabete Mellitus

Interventions

  • Implementation of program based on WHO HEARTS-D guidelinesOther

    This study uses an interrupted time series design to compare diabetes screening, diagnosis, treatment, and control across a 12-month pre-implementation period and a 24-month implementation period in 10 primary healthcare centers in Nigeria's Federal Capital Territory. Sites previously demonstrated capacity to deliver hypertension care and will continue hypertension services while expanding to diabetes care through the HEARTS diabetes module (HEARTS-D). Pre-implementation includes registry setup and provision of glucometers without diabetes treatment training. Implementation includes HEARTS-D training, supply provision, expansion of the drug revolving fund to diabetes medicines, and quarterly supportive supervision.

  • MetforminDrug

    Description: Oral biguanide used as first-line glucose-lowering therapy within the HEARTS-D stepped-care protocol. Dosing per protocol: 500 mg once daily (Step 1), 1000 mg once daily (Step 2), 1000 mg twice daily (Step 3 and Step 4). Supplied through the expanded drug revolving fund during the implementation period.

  • GlimepirideDrug

    Oral sulfonylurea used as add-on therapy at Step 4 of the HEARTS-D stepped-care protocol when blood glucose remains uncontrolled on metformin. Starting dose 1 mg once daily, titrated by 1-2 mg to a maximum of 8 mg daily. Supplied through the expanded drug revolving fund during the implementation period.

  • Point-of-care blood glucose monitor (glucometer) and compatible test stripsDevice

    Point-of-care capillary blood glucose monitor with compatible single-use test strips and lancets, used at participating primary health centers for diabetes screening, diagnosis, and monitoring per WHO HEARTS-D. Glucometers and test strips are provided to all sites during pre-implementation (registry setup) and replenished during implementation through the supply chain and drug revolving fund.

  • HEARTS-D training and quarterly supportive supervision for community health extension workers (CHEWs)Behavioral

    Structured training of CHEWs on the HEARTS-D protocol covering diabetes screening, diagnosis, stepped-care treatment, follow-up, and referral, delivered at the start of the implementation period and reinforced by quarterly supportive supervision visits with audit-and-feedback throughout the 24-month implementation period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose of quarterly supportive supervision visits measured by the proportion of observed/expected visits during the implementation period.Time frame: 36 months
  2. Difference in 6-month rolling average of blood glucose control in patients with diabetes (random blood glucose ≤11.1 mmol/L while receiving treatment; or fasting plasma glucose/HbA1c within target, as available) per WHO HEARTS-D, pre- vs. implementationTime frame: 36 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • New Township Abaji

    Abaji, Nigeria · Recruiting

  • Gbagarape PHC

    Abuja, Nigeria · Recruiting

  • Gidan Mangoro

    Abuja, Nigeria · Recruiting

  • Pyakasa PHC

    Abuja, Nigeria · Recruiting

  • Byazhin

    Bwari, Nigeria · Recruiting

  • Gtc Gwagwalada

    Gwagwalada, Nigeria · Recruiting

  • Old Kutunku

    Gwagwalada, Nigeria · Recruiting

  • Kuje PHC

    Kuje, Nigeria · Recruiting

  • Dabi Bako

    Kwali, Nigeria · Recruiting

  • KAWLI

    Kwali, Nigeria · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.